雾化噬菌体治疗MRSA肺炎的大鼠实验研究
该研究在大鼠呼吸机相关肺炎模型中比较雾化噬菌体、静脉噬菌体、两者联用、利奈唑胺及利奈唑胺联合雾化噬菌体对耐甲氧西林金黄色葡萄球菌(MRSA)肺炎的疗效,主要终点为96小时生存率;雾化与静脉噬菌体单用各使50%动物存活,联用达91%,高于任一单药。
要点
- 雾化噬菌体与静脉噬菌体单用均使50%动物免于重症MRSA肺炎死亡。
- 雾化联合静脉噬菌体生存率达91%,优于任一单药。
- 利奈唑胺联合雾化噬菌体未显示协同作用,生存率55%。
核心结论
- 雾化噬菌体治疗在实验动物模型中对MRSA肺炎显示潜力,值得进一步研究以应用于人类。
研究设计与样本
- 大鼠实验研究:动物先接受4小时通气,随后诱导肺炎,随机接受雾化噬菌体、静脉噬菌体、两者联用、静脉利奈唑胺或利奈唑胺联合雾化噬菌体。
- 噬菌体于2、12、24、48、72小时给药,利奈唑胺于2、12、24、36、48、60、72小时给药。
- 主要终点为96小时生存率,次要终点为组织细菌与噬菌体计数及肺部组织病理学评分。
主要发现
- 雾化噬菌体与静脉噬菌体各使50%动物从重症MRSA肺炎中存活(与安慰剂对照相比P < .01)。
- 雾化联合静脉噬菌体使91%动物存活,高于任一单药(P < .05)。
- 标准治疗抗生素利奈唑胺使38%动物存活。
- 利奈唑胺联合雾化噬菌体未产生协同作用,生存率为55%。
临床怎么用
- 提示雾化噬菌体可能作为MRSA肺炎的辅助治疗方向,尤其与静脉噬菌体联用。
- 利奈唑胺联合雾化噬菌体在本模型中未见协同,临床联合策略需谨慎评估。
局限性
- 结果为动物实验数据,尚不能直接外推至人类临床应用。
- 原文未报告样本量、置信区间等详细统计信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal method for delivering phages in the context of ventilator-associated pneumonia (VAP) is unknown. In the current study, we assessed the utility of aerosolized phages (aerophages) for experimental methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. METHODS: Rats were ventilated for 4 hours before induction of pneumonia. Animals received one of the following: (1) aerophages; (2) intravenous (IV) phages; (3) a combination of IV and aerophages; (4) IV linezolid; or (5) a combination of IV linezolid and aerophages. Phages were administered at 2, 12, 24, 48, and 72 hours, and linezolid was administered at 2, 12, 24, 36, 48, 60, and 72 hours. The primary outcome was survival at 96 hours. Secondary outcomes were bacterial and phage counts in tissues and histopathological scoring of the lungs. RESULTS: Aerophages and IV phages each rescued 50% of animals from severe MRSA pneumonia (P < .01 compared with placebo controls). The combination of aerophages and IV phages rescued 91% of animals, which was higher than either monotherapy (P < .05). Standard-of-care antibiotic linezolid rescued 38% of animals. However, linezolid and aerophages did not synergize in this setting (55% survival). CONCLUSIONS: Aerosolized phage therapy showed potential for the treatment of MRSA pneumonia in an experimental animal model and warrants further investigation for application in humans.
引用
- Prazak J, Valente LG, Iten M, et al. Benefits of Aerosolized Phages for the Treatment of Pneumonia Due to Methicillin-Resistant Staphylococcus aureus: An Experimental Study in Rats. J Infect Dis. 2022. PMID: 33668071. doi:10.1093/infdis/jiab112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。